Curanex, botanical drug developer, files for $10M IPO
Curanex Pharmaceuticals (CURX) has filed for a proposed $10M initial public offering. According to an SEC filing, Curanex is ...
Radiopharm locks in drug maker for US brain cancer trial
Radiopharm Theranostics has joined forces with US-based radiopharmaceutical manufacturer BAMF Health to trial its brain ...
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets ...
Outsourcing-pharma10d
Antag Therapeutics gets FDA clearance to start clinical trials with new obesity drug
The FDA decision will enable Antag Therapeutics to initiate the clinical development of its lead candidate drug, a ...
Lantern Pharma’s Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and ...
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseasesKT-621 is expected ...
Business Wire1d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
Zacks.com on MSN3d
GSK's NDA for UTI Drug Gepotidacin Gets FDA's Priority Review
GSK plc GSK announced that the FDA has accepted its new drug application (NDA) seeking approval for its investigational, ...
Business Insider12d
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial
today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a ...
Nasdaq12d
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class ... of its Investigational New Drug (IND) application ...
Nasdaq11d
Ocugen: FDA Lifts Clinical Hold On Investigational New Drug Application For Phase 1 Trial Of OCU200
(RTTNews) - Ocugen (OCGN) reported that the FDA has lifted the clinical hold on the investigational new drug application for the Phase 1 clinical trial evaluating OCU200, a recombinant fusion ...